<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Neurizon Therapeutics Limited — News on 6ix</title>
<link>https://6ix.com/company/neurizon-therapeutics-limited</link>
<description>Latest news and press releases for Neurizon Therapeutics Limited on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 16 Apr 2026 03:48:15 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/neurizon-therapeutics-limited" rel="self" type="application/rss+xml" />
<item>
<title>Placement of Entitlement Offer Shortfall</title>
<link>https://6ix.com/company/neurizon-therapeutics-limited/news/placement-of-entitlement-offer-shortfall-5</link>
<guid isPermaLink="true">https://6ix.com/company/neurizon-therapeutics-limited/news/placement-of-entitlement-offer-shortfall-5</guid>
<pubDate>Thu, 16 Apr 2026 03:48:15 GMT</pubDate>
<description>Placement of Entitlement Offer Shortfall</description>
</item>
<item>
<title>NUZ-001 Data Shows Multi-Pathway Protein Clearance</title>
<link>https://6ix.com/company/neurizon-therapeutics-limited/news/nuz-001-data-shows-multi-pathway-protein-clearance</link>
<guid isPermaLink="true">https://6ix.com/company/neurizon-therapeutics-limited/news/nuz-001-data-shows-multi-pathway-protein-clearance</guid>
<pubDate>Wed, 01 Apr 2026 03:07:04 GMT</pubDate>
<description>NUZ-001 Data Shows Multi-Pathway Protein Clearance</description>
</item>
<item>
<title>Neurizon announces leadership transition</title>
<link>https://6ix.com/company/neurizon-therapeutics-limited/news/neurizon-announces-leadership-transition</link>
<guid isPermaLink="true">https://6ix.com/company/neurizon-therapeutics-limited/news/neurizon-announces-leadership-transition</guid>
<pubDate>Mon, 16 Mar 2026 01:40:04 GMT</pubDate>
<description>Neurizon announces leadership transition</description>
</item>
<item>
<title>Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial</title>
<link>https://6ix.com/company/neurizon-therapeutics-limited/news/neurizon-initiates-dosing-of-nuz-001-in-healey-als-platform-trial</link>
<guid isPermaLink="true">https://6ix.com/company/neurizon-therapeutics-limited/news/neurizon-initiates-dosing-of-nuz-001-in-healey-als-platform-trial</guid>
<pubDate>Thu, 26 Feb 2026 14:00:00 GMT</pubDate>
<description>Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotechnology company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce that the first participant has been dosed in Regimen I of the HEALEY ALS Platform Trial evaluating Neurizon's lead candidate, NUZ-001, for the treatment of amyotrophic lateral sclerosis (ALS).</description>
</item>
<item>
<title>Neurizon Initiates Dosing in HEALEY ALS Platform Trial</title>
<link>https://6ix.com/company/neurizon-therapeutics-limited/news/neurizon-initiates-dosing-in-healey-als-platform-trial</link>
<guid isPermaLink="true">https://6ix.com/company/neurizon-therapeutics-limited/news/neurizon-initiates-dosing-in-healey-als-platform-trial</guid>
<pubDate>Thu, 26 Feb 2026 03:31:08 GMT</pubDate>
<description>Neurizon Initiates Dosing in HEALEY ALS Platform Trial</description>
</item>
<item>
<title>Appendix 4D - Half-year Financial Report - 31 December 2025</title>
<link>https://6ix.com/company/neurizon-therapeutics-limited/news/appendix-4d-half-year-financial-report-31-december-2025</link>
<guid isPermaLink="true">https://6ix.com/company/neurizon-therapeutics-limited/news/appendix-4d-half-year-financial-report-31-december-2025</guid>
<pubDate>Wed, 25 Feb 2026 04:12:04 GMT</pubDate>
<description>Appendix 4D - Half-year Financial Report - 31 December 2025</description>
</item>
<item>
<title>Appendix 4C & Quarterly Update</title>
<link>https://6ix.com/company/neurizon-therapeutics-limited/news/appendix-4c-and-quarterly-update</link>
<guid isPermaLink="true">https://6ix.com/company/neurizon-therapeutics-limited/news/appendix-4c-and-quarterly-update</guid>
<pubDate>Fri, 30 Jan 2026 03:19:21 GMT</pubDate>
<description>Appendix 4C & Quarterly Update</description>
</item>
<item>
<title>Neurizon secures $6million R&D Tax Incentive Rebate</title>
<link>https://6ix.com/company/neurizon-therapeutics-limited/news/neurizon-secures-dollar6million-randd-tax-incentive-rebate</link>
<guid isPermaLink="true">https://6ix.com/company/neurizon-therapeutics-limited/news/neurizon-secures-dollar6million-randd-tax-incentive-rebate</guid>
<pubDate>Thu, 29 Jan 2026 07:33:09 GMT</pubDate>
<description>Neurizon secures $6million R&D Tax Incentive Rebate</description>
</item>
<item>
<title>Neurizon Completes Entitlement Offer</title>
<link>https://6ix.com/company/neurizon-therapeutics-limited/news/neurizon-completes-entitlement-offer</link>
<guid isPermaLink="true">https://6ix.com/company/neurizon-therapeutics-limited/news/neurizon-completes-entitlement-offer</guid>
<pubDate>Tue, 27 Jan 2026 04:17:04 GMT</pubDate>
<description>Neurizon Completes Entitlement Offer</description>
</item>
<item>
<title>Global Trademark Protection Secured Across Key Markets</title>
<link>https://6ix.com/company/neurizon-therapeutics-limited/news/global-trademark-protection-secured-across-key-markets</link>
<guid isPermaLink="true">https://6ix.com/company/neurizon-therapeutics-limited/news/global-trademark-protection-secured-across-key-markets</guid>
<pubDate>Tue, 20 Jan 2026 04:09:12 GMT</pubDate>
<description>Global Trademark Protection Secured Across Key Markets</description>
</item>
<item>
<title>Regulatory and Development Update</title>
<link>https://6ix.com/company/neurizon-therapeutics-limited/news/regulatory-and-development-update</link>
<guid isPermaLink="true">https://6ix.com/company/neurizon-therapeutics-limited/news/regulatory-and-development-update</guid>
<pubDate>Fri, 02 Jan 2026 03:08:11 GMT</pubDate>
<description>Regulatory and Development Update</description>
</item>
<item>
<title>New Funding Secured for HEALEY ALS Platform Trial</title>
<link>https://6ix.com/company/neurizon-therapeutics-limited/news/new-funding-secured-for-healey-als-platform-trial</link>
<guid isPermaLink="true">https://6ix.com/company/neurizon-therapeutics-limited/news/new-funding-secured-for-healey-als-platform-trial</guid>
<pubDate>Tue, 23 Dec 2025 04:13:15 GMT</pubDate>
<description>New Funding Secured for HEALEY ALS Platform Trial</description>
</item>
<item>
<title>Equity Raising Presentation</title>
<link>https://6ix.com/company/neurizon-therapeutics-limited/news/equity-raising-presentation-19</link>
<guid isPermaLink="true">https://6ix.com/company/neurizon-therapeutics-limited/news/equity-raising-presentation-19</guid>
<pubDate>Tue, 23 Dec 2025 04:11:05 GMT</pubDate>
<description>Equity Raising Presentation</description>
</item>
<item>
<title>Trading Halt</title>
<link>https://6ix.com/company/neurizon-therapeutics-limited/news/trading-halt-555</link>
<guid isPermaLink="true">https://6ix.com/company/neurizon-therapeutics-limited/news/trading-halt-555</guid>
<pubDate>Fri, 19 Dec 2025 03:33:14 GMT</pubDate>
<description>Trading Halt</description>
</item>
<item>
<title>FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial</title>
<link>https://6ix.com/company/neurizon-therapeutics-limited/news/fda-clears-nuz-001-entry-204900844</link>
<guid isPermaLink="true">https://6ix.com/company/neurizon-therapeutics-limited/news/fda-clears-nuz-001-entry-204900844</guid>
<pubDate>Thu, 11 Dec 2025 20:49:00 GMT</pubDate>
<description>Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce that the Sean M. Healey & AMG Center for ALS at Mass General Brigham has received clearance from the US Food and Drug Administration (FDA) to proceed with Neurizon's NUZ-001 regimen in the HEALEY ALS Platform Trial (ClinicalTrials.gov identifier: NCT04297683) following co</description>
</item>
<item>
<title>Neurizon Completes GMP Tablet Registration Batches</title>
<link>https://6ix.com/company/neurizon-therapeutics-limited/news/neurizon-completes-gmp-tablet-registration-batches</link>
<guid isPermaLink="true">https://6ix.com/company/neurizon-therapeutics-limited/news/neurizon-completes-gmp-tablet-registration-batches</guid>
<pubDate>Thu, 04 Dec 2025 03:15:12 GMT</pubDate>
<description>Neurizon Completes GMP Tablet Registration Batches</description>
</item>
<item>
<title>Elanco executive appointed as Neurizon's Board Observer</title>
<link>https://6ix.com/company/neurizon-therapeutics-limited/news/elanco-executive-appointed-neurizons-board-231500643</link>
<guid isPermaLink="true">https://6ix.com/company/neurizon-therapeutics-limited/news/elanco-executive-appointed-neurizons-board-231500643</guid>
<pubDate>Wed, 26 Nov 2025 23:15:00 GMT</pubDate>
<description>Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms Justine Conway as a Board Observer. Ms Conway currently serves as Global Head of Business Development at Elanco Animal Health ("Elanco") (NYSE: ELAN) and will participate in Neurizon's Board activities as Elanco's designated representative.</description>
</item>
<item>
<title>Neurizon to present Q1 FY2026 Results</title>
<link>https://6ix.com/company/neurizon-therapeutics-limited/news/neurizon-to-present-q1-fy2026-results</link>
<guid isPermaLink="true">https://6ix.com/company/neurizon-therapeutics-limited/news/neurizon-to-present-q1-fy2026-results</guid>
<pubDate>Fri, 31 Oct 2025 02:56:07 GMT</pubDate>
<description>Neurizon to present Q1 FY2026 Results</description>
</item>
<item>
<title>Australian Patent Granted for NUZ-001</title>
<link>https://6ix.com/company/neurizon-therapeutics-limited/news/australian-patent-granted-for-nuz-001</link>
<guid isPermaLink="true">https://6ix.com/company/neurizon-therapeutics-limited/news/australian-patent-granted-for-nuz-001</guid>
<pubDate>Tue, 21 Oct 2025 02:29:16 GMT</pubDate>
<description>Australian Patent Granted for NUZ-001</description>
</item>
<item>
<title>FDA Lifts Clinical Hold on NUZ-001</title>
<link>https://6ix.com/company/neurizon-therapeutics-limited/news/fda-lifts-clinical-hold-nuz-060600497</link>
<guid isPermaLink="true">https://6ix.com/company/neurizon-therapeutics-limited/news/fda-lifts-clinical-hold-nuz-060600497</guid>
<pubDate>Mon, 06 Oct 2025 06:06:00 GMT</pubDate>
<description>Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its lead investigational drug, NUZ‑001. This decision marks a pivotal regulatory milestone for Neurizon and the ALS community, clearing the way for Phase 2/3 development of NUZ-001 as part of the HEALEY ALS</description>
</item>
</channel>
</rss>